Projects per year
Fingerprint
Dive into the research topics where Robert Kortum is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Isoform-specific signaling as a determinant of RAS-driven oncogenesis
Kortum, R. (PI)
1/02/22 → 31/01/27
Project: Research
-
Preventing Therapeutic Resistance in RAS-mutated Pediatric Cancers
Kortum, R. (PI)
1/02/22 → 31/01/25
Project: Research
-
SOS2 Is a Tractable Therapeutic Target to Limit Therapeutic Resistance in Non-Small Cell Lung Cancer
Kortum, R. (PI)
Congressionally Directed Medical Research Programs
1/08/19 → 31/07/21
Project: Research
-
SOS2 Is a Tractable Therapeutic Target to Limit Therapeutic Resistance in Non-Small Cell Lung Cancer
Kortum, R. (PI)
1/08/19 → 31/07/21
Project: Research
-
Interrogating SOS1/2 (Son of Sevenless 1 and 2) as Therapeutic Targets in Treatment-Resistant EGFR and K-ras-Driven Lung Cancer
Kortum, R. (PI)
1/06/17 → 31/05/19
Project: Research
-
Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer
Price, H. E., Stauffer, S., Lee, H., Isanogle, K. A., Wu, Y., Powell, K., Baker, A., Stauffer, L., Perciaccante, A. J., Jewell, C. P., Hernandez, E. R., Aljabri, A. K., Odeniyide, P., Pratilas, C. A., Burgan, W., Edmondson, E. F., Difilippantonio, S., Kortum, R. L., Shern, J. F. & Jenkins, L. M. & 2 others, , 1 May 2026, In: Molecular Cancer Therapeutics. 25, 5, p. 727-744 18 p.Research output: Contribution to journal › Article › peer-review
Open Access -
SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma
Daley, B. R., Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Gerlach, D., Hofmann, M. H., Kostyrko, K., LaMorte, J. P., Linke, A. J., Beckley, Z., Frank, A. M., Lewis, R. E., Wilkerson, M. D., Dalgard, C. L. & Kortum, R. L., 1 Jan 2025, In: Cancer Research. 85, 1, p. 118-133 16 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations -
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in EGFR-mutant lung cancer
Daley, B. R., Theard, P. L., Hughes, J. M., Finniff, B. A., Hofmann, M. H., Kostyrko, K., Schenk, R. L., Vieira, H. M., Askew, J. W., Lewis, R. E. & Kortum, R. L., 25 Nov 2025, In: Science Signaling. 18, 914, eaea2788.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers
Sealover, N. E., Finniff, B. A., Hughes, J. M., Sheffels, E., Lee, H., Lamorte, J. P., Gambhir, V., Beckley, Z., Linke, A., Wilkerson, M. D., Yohe, M. E. & Kortum, R. L., 16 Sep 2025, In: Science Signaling. 18, 904, eadx5186.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies
Sealover, N. E., Theard, P. T., Hughes, J. M., Linke, A. J., Daley, B. R. & Kortum, R. L., 19 Jan 2024, In: iScience. 27, 1, 108711.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations
Press/Media
-
$1.7M DOD grant funds virtual cancer center to support research into military health
16/09/25 → 17/09/25
4 items of Media coverage
Press/Media
-
University of Arizona: $1.7M DOD grant funds virtual cancer center to support research into military health
16/09/25
1 item of Media coverage
Press/Media